Literature DB >> 33797568

Correlation between melatonin concentration and cytokines in cervical mucus in positive samples for the presence of human papillomavirus.

Aron Carlos de Melo Cotrim1, Eduardo Luzia França2, Jordana Santos Martins3, Katleyn Polizeli Galvão Silva3, Mahmi Fujimori3, Yehya Chakib Ghalfi4, Izabela Trindade Machado4, Adenilda Cristina Honorio-França3, Inês Aparecida Tozetti1.   

Abstract

The human papillomavirus (HPV) is the main causative agent of cervical cancer, characterized by neoplastic lesions in the cervix. Based on the morphology of the cells of the uterine cervix, the findings are classified as negative intraepithelial lesions for malignancies, low-grade squamous intraepithelial lesions, high-grade squamous intraepithelial lesions (HSILs), atypical squamous cells of undetermined significance and atypical squamous cells of undetermined significance without excluding HSILs (ASCs-H). The progression of neoplastic lesions is related to the cervix's microenvironmental inflammatory process and mediated by the expression and stimulation of cytokines. Cervical mucus is a viscous liquid secretion composed of proteins, inorganic components, pro-and anti-inflammatory agents, and an important protective barrier. This study aimed to quantify and correlate cytokines IL-6, IL-8, and IL-10 and Melatonin in cervical mucus. According to the results, a decrease in MLT was observed in LSIL, HSI, and ASC-H groups than in the NILM group. The cytokines IL-6 and IL-8 showed greater expression in the LSIL and HSIL groups than the NILM group. HSIL group showed a negative correlation between the MLT and IL-6 and IL-8 concentrations. In the ASC-US group, IL8 level was positively correlated to MLT levels. We suggest that IL-6, IL-8, and MLT levels in HSIL groups are decisive for the progression of neoplastic lesions in HPV infections. New cervical cancer treatment strategies may include cytokine and melatonin control targets for effective immunotherapy.

Entities:  

Keywords:  Cervical mucus; Cytokines; HPV; HSIL; Melatonin

Year:  2021        PMID: 33797568     DOI: 10.1007/s00262-021-02922-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  5 in total

Review 1.  Melatonin: Nature's most versatile biological signal?

Authors:  S R Pandi-Perumal; V Srinivasan; G J M Maestroni; D P Cardinali; B Poeggeler; R Hardeland
Journal:  FEBS J       Date:  2006-07       Impact factor: 5.542

2.  Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells.

Authors:  Carlos Martínez-Campa; Alicia González; Maria Dolores Mediavilla; Carolina Alonso-González; Emilio J Sánchez-Barceló; Samuel Cos
Journal:  Breast Cancer Res Treat       Date:  2005-10-22       Impact factor: 4.872

3.  Melatonin inhibits Prevotella intermedia lipopolysaccharide-induced production of nitric oxide and interleukin-6 in murine macrophages by suppressing NF-κB and STAT1 activity.

Authors:  Eun-Young Choi; Ji-Young Jin; Ju-Youn Lee; Jeom-Il Choi; In Soon Choi; Sung-Jo Kim
Journal:  J Pineal Res       Date:  2010-12-16       Impact factor: 13.007

4.  [CD4 and CD8 T lymphocytes and NK cells in the stroma of the uterine cervix of women infected with human papillomavirus].

Authors:  Daniella Borges Alves; Inês Aparecida Tozetti; Flávia Almeida Gatto; Fernanda Cassandri; Alda Maria Teixeira Ferreira; Fernandes Carlos Eurico Dos Santos; Gustavo Ribeiro Falcão; Ilzia Doraci Lins Scapulatempo; Cacilda Tezelli Junqueira Padovani; Maria Auxiliadora Gomes Sandim Abdo
Journal:  Rev Soc Bras Med Trop       Date:  2010 Jul-Aug       Impact factor: 1.581

5.  Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.

Authors:  Marc Arbyn; Elisabete Weiderpass; Laia Bruni; Silvia de Sanjosé; Mona Saraiya; Jacques Ferlay; Freddie Bray
Journal:  Lancet Glob Health       Date:  2019-12-04       Impact factor: 26.763

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.